natgillin/translations-raw huggingface dataset:
Der er en øget risiko for tromboemboliske hændelser hos patienter med cancer, som behandles med rekombinant humant erytropoietin, og en negativ virkning på samlet overlevelse kan ikke udelukkes.
63 thromboembolic events in patients with cancer treated with recombinant human erythropoietin and a negative impact on overall survival cannot be excluded.
Dinatriumfosfat- dihydrat Natriumdihydrogenfosfat- dihydrat
Disodium phosphate dihydrate Sodium dihydrogen phosphate dihydrate Sodium chloride Calcium chloride dihydrate Polysorbate 20 Glycine
69 Natriumklorid Kalciumklorid- dihydrat Polysorbat 20 Glycin Leucin Isoleucin Treonin Glutaminsyre Fenylalanin Vand til injektioner Natriumhydroxid (til justering af pH- værdien) Saltsyre (til justering af pH- værdien)
64 Leucine Isoleucine Threonine Glutamic acid Phenylalanine Water for injections Sodium hydroxide (pH adjuster) Hydrochloric acid (pH adjuster)
70 Dette medicinske produkt er kun til engangsbrug.
This medicinal product is for single use only.
Ikke anvendte lægemidler samt affald heraf bør destrueres i henhold til lokale retningslinier.
65 Any unused product or waste material should be disposed of in accordance with local requirements.
Silapo 6000 IU/ 0, 6 ml injektionsvæske, opløsning i en fyldt injektionssprøjte
Silapo 6000 IU/0.6ml solution for injection in pre-filled syringe
72 − Behandling af symptomatisk anæmi hos voksne og pædiatriske patienter med kronisk nyreinsufficiens
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patientsIn patients with chronic renal failure the medicinal product has to be administered intravenously (see section 4.4)
73 Dosis (IU/ kg 3 gange ugentligt)
Dose (IU/kg given 3x week)
74 Hvis hæmoglobinet er steget med mindst 1 g/ dl (0, 62 mmol/ l), eller reticulocyttællingen er steget til ≥ 40. 000 celler/ µl over baseline efter 4 ugers behandling, bør der fortsættes med dosis på 150 IU/ kg 3 gange om ugen eller 450 IU/ kg 1 gang ugentligt.
If the haemoglobin has increased by at least 1 g/dl (0.62 mmol/l) or the reticulocyte count has increased ≥ 40,000 cells/µl above baseline after 4 weeks of treatment, the dose should remain at 150 IU/kg 3 times per week or 450 IU/kg once weekly.
Retikulocyttalsstigning ≥ 40. 000/ mikroliter eller stigning i Hb med ≥ 1 g/ dl
69 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
76 Alle patienter, som behandles med Silapo, bør have et tilstrækkeligt jerntilskud (fx 200 mg usammensat jern oralt dagligt) under hele behandlingen.
200 mg oral elemental iron daily) throughout the course of treatment.
77 falder ferritinværdierne i serum samtidig med stigningen i hæmatokrit.
In most cases, the ferritin values in the serum fall simultaneously with the rise in packed cell volume.
78 anbefales der regelmæssig monitorering af reticulocyttal Hyperkalæmi er observeret i isolerede tilfælde.
Hyperkalaemia has been observed in isolated cases.
I kontrollerede kliniske forsøg har brug af epoetin alfa og andre erytropoiese- stimulerende stoffer (ESA' er) vist: • kortere tid til tumorprogression hos patienter med fremskreden hoved - og halscancer, som får strålebehandling, når stofferne administreres for at tilstræbe et hæmoglobinniveau, som er højere end 14 g/ dl (8, 7 mmol/ l),
In controlled clinical studies, use of Epoetin alfa and other erythropoiesis-stimulating agents (ESAs) have shown: • shortened time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a haemoglobin of greater than 14 g/dl (8.7 mmol/l), • shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a haemoglobin of 12-14 g/dl (7.5 -8.7 mmol/l),
79
73
80 cerebrovaskulær hændelse (cerebral blødning og cerebral infarkt), forbigående iskæmiske anfald, dyb venetrombose, arterietrombose, pulmonal emboli, aneurismer, retinal trombose samt tilstopning af en kunstig nyre hos patienter, der får erythropoietiske midler.
Thrombotic/vascular events, such as myocardial ischaemia, myocardial infarction, cerebrovascular accidents (cerebral haemorrhage and cerebral infarction), transient ischaemic attacks, deep vein thrombosis, arterial thrombosis, pulmonary emboli, aneurysms, retinal thrombosis, and clotting of an artificial kidney have been reported in patients receiving erythropoietic agents.
Disse stigninger i blodtrykket kan behandles medicinsk.
The se increases in blood pressure can be treated with medicinal products.
Derfor skal disse patienter rutinemæssigt have volumenerstatningsbehandling.
The refore, routine volume replacement should be performed in such patients.
Hvorvidt disse rater også gælder for administration af rekombinant humant erytropoietin til patienter med cancer, som behandles med kemoterapi, for at opnå hæmoglobinkoncentrationer på mindre end 13 g/ dl, er uklart, fordi der i de gennemgåede data kun var få patienter med disse karakteristika.
76 apply to the administration of recombinant human erythropoietin to patients with cancer, treated with chemotherapy to achieve haemoglobin concentrations less than 13 g/dl, is unclear because few patients with these characteristics were included in the data reviewed.
Dinatriumfosfat- dihydrat Natriumdihydrogenfosfat- dihydrat
Disodium phosphate dihydrate Sodium dihydrogen phosphate dihydrate Sodium chloride Calcium chloride dihydrate Polysorbate 20 Glycine Leucine Isoleucine
83 Natriumklorid Kalciumklorid- dihydrat Polysorbat 20 Glycin Leucin Isoleucin Treonin Glutaminsyre Fenylalanin Vand til injektioner Natriumhydroxid (til justering af pH- værdien) Saltsyre (til justering af pH- værdien)
77 Threonine Glutamic acid Phenylalanine Water for injections Sodium hydroxide (pH adjuster) Hydrochloric acid (pH adjuster)
84 Dette medicinske produkt er kun til engangsbrug.
This medicinal product is for single use only.
Silapo 8000 IU/ 0, 8 ml injektionsvæske, opløsning i en fyldt injektionssprøjte
Silapo 8000 IU/0.8ml solution for injection in pre-filled syringe
4. 4). − Behandling af anæmi og reduktion af transfusionsbehov hos voksne patienter i kemoterapi for massive tumorer, malignt lymfom eller multipelt myelom og med risiko ved transfusion vurderet ud fra patientens almentilstand (fx kardiovaskulær tilstand, præeksisterende anæmi ved kemoterapistart). − Silapo kan anvendes til at øge udbyttet af autologt blod fra patienterne i et prædonationsprogram.
4.1 Therapeutic indications − Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients: o Treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis (See section 4.4). o Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis (See section 4.4). − Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy). − Silapo can be used to increase the yield of autologous blood from patients in a predonation programme.
86 − Behandling af symptomatisk anæmi hos voksne og pædiatriske patienter med kronisk nyreinsufficiens
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patientsIn patients with chronic renal failure the medicinal product has to be administered intravenously (see section 4.4)
87 Dosis (IU/ kg 3 gange ugentligt)
Dose (IU/kg given 3x week)
88 med en initialdosis på 450 IU/ kg subkutant 1 gang ugentligt.
Alternatively, Silapo can be administered at an initial dose of 450 IU/kg subcutaneously once weekly.
Retikulocyttalsstigning ≥ 40. 000/ mikroliter eller stigning i Hb med ≥ 1 g/ dl
82 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
90 Alle patienter, som behandles med Silapo, bør have et tilstrækkeligt jerntilskud (fx 200 mg usammensat jern oralt dagligt) under hele behandlingen.
200 mg oral elemental iron daily) throughout the course of treatment.
Alternativt kan der, for at skylle slangen og sikre tilfredsstillende overførsel af produktet til kredsløbet, gives en injektion til sidst i dialysesessionen via fistelnålslangen, efterfulgt af 10 ml natriumkloridopløsning, 9 mg/ ml (0, 9%).
Alternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection to rinse the tubing and ensure satisfactory injection of the medicinal product into the circulation.
91 falder ferritinværdierne i serum samtidig med stigningen i hæmatokrit.
In most cases, the ferritin values in the serum fall simultaneously with the rise in packed cell volume.
92 anbefales der regelmæssig monitorering af reticulocyttal Hyperkalæmi er observeret i isolerede tilfælde.
Hyperkalaemia has been observed in isolated cases.
93
86
94 cerebrovaskulær hændelse (cerebral blødning og cerebral infarkt), forbigående iskæmiske anfald, dyb venetrombose, arterietrombose, pulmonal emboli, aneurismer, retinal trombose samt tilstopning af en kunstig nyre hos patienter, der får erythropoietiske midler.
Thrombotic/vascular events, such as myocardial ischaemia, myocardial infarction, cerebrovascular accidents (cerebral haemorrhage and cerebral infarction), transient ischaemic attacks, deep vein thrombosis, arterial thrombosis, pulmonary emboli, aneurysms, retinal thrombosis, and clotting of an artificial kidney have been reported in patients receiving erythropoietic agents.
Hvorvidt disse rater også gælder for administration af rekombinant humant erytropoietin til patienter med cancer, som behandles med kemoterapi, for at opnå hæmoglobinkoncentrationer på mindre end 13 g/ dl, er uklart, fordi der i de gennemgåede data kun var få patienter med disse karakteristika.
89 apply to the administration of recombinant human erythropoietin to patients with cancer, treated with chemotherapy to achieve haemoglobin concentrations less than 13 g/dl, is unclear because few patients with these characteristics were included in the data reviewed.
97 Natriumklorid Kalciumklorid- dihydrat Polysorbat 20 Glycin Leucin Isoleucin Treonin Glutaminsyre Fenylalanin Vand til injektioner Natriumhydroxid (til justering af pH- værdien) Saltsyre (til justering af pH- værdien)
90 Threonine Glutamic acid Phenylalanine Water for injections Sodium hydroxide (pH adjuster) Hydrochloric acid (pH adjuster)
98 Dette medicinske produkt er kun til engangsbrug.
This medicinal product is for single use only.
Silapo 10000 IU/ 1, 0 ml injektionsvæske, opløsning i en fyldt injektionssprøjte
Silapo 10000 IU/1.0ml solution for injection in pre-filled syringe
100 − Behandling af symptomatisk anæmi hos voksne og pædiatriske patienter med kronisk nyreinsufficiens
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patientsIn patients with chronic renal failure the medicinal product has to be administered intravenously (see section 4.4)
101 Dosis (IU/ kg 3 gange ugentligt)
Dose (IU/kg given 3x week)
Det er nødvendigt, at en læge bedømmer den individuelle patients kliniske forløb og tilstand.
A naemia symptoms and sequelae may vary with age, gender, and overall burden of disease; a physician´s evaluation of the individual patient´s clinical course and condition is necessary.
102 med en initialdosis på 450 IU/ kg subkutant 1 gang ugentligt.
Alternatively, Silapo can be administered at an initial dose of 450 IU/kg subcutaneously once weekly.
Retikulocyttalsstigning ≥ 40. 000/ mikroliter eller stigning i Hb med ≥ 1 g/ dl
95 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
104 Alle patienter, som behandles med Silapo, bør have et tilstrækkeligt jerntilskud (fx 200 mg usammensat jern oralt dagligt) under hele behandlingen.
200 mg oral elemental iron daily) throughout the course of treatment.
105 falder ferritinværdierne i serum samtidig med stigningen i hæmatokrit.
In most cases, the ferritin values in the serum fall simultaneously with the rise in packed cell volume.
106 Hyperkalæmi er observeret i isolerede tilfælde.
Hyperkalaemia has been observed in isolated cases.
I kontrollerede kliniske forsøg har brug af epoetin alfa og andre erytropoiese- stimulerende stoffer (ESA' er) vist: • kortere tid til tumorprogression hos patienter med fremskreden hoved - og halscancer, som får strålebehandling, når stofferne administreres for at tilstræbe et hæmoglobinniveau, som er højere end 14 g/ dl (8, 7 mmol/ l), • kortere samlet overlevelse og flere dødsfald, som tilskrives sygdomsprogression ved 4
In controlled clinical studies, use of Epoetin alfa and other erythropoiesis-stimulating agents (ESAs) have shown: • shortened time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a haemoglobin of greater than 14 g/dl (8.7 mmol/l), • shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a haemoglobin of 12-14 g/dl (7.5 -8.7 mmol/l),
107 måneder hos patienter med metastatisk brystcancer, som får kemoterapi, når stofferne gives for at tilstræbe et hæmoglobinniveau på 12- 14 g/ dl (7, 5- 8, 7 mmol/ l),
99
109 Erytropoietins tilsyneladende molekylvægt er 32000- 40000 Dalton.
The apparent molecular weight of erythropoietin is 32,000-40,000 Dalton.
Hvorvidt disse rater også gælder for administration af rekombinant humant erytropoietin til patienter med cancer, som behandles med kemoterapi, for at opnå hæmoglobinkoncentrationer på mindre end 13 g/ dl, er uklart, fordi der i de gennemgåede data kun var få patienter med disse karakteristika.
102 apply to the administration of recombinant human erythropoietin to patients with cancer, treated with chemotherapy to achieve haemoglobin concentrations less than 13 g/dl, is unclear because few patients with these characteristics were included in the data reviewed.
111 Kalciumklorid- dihydrat Polysorbat 20 Glycin Leucin Isoleucin Treonin Glutaminsyre Fenylalanin Vand til injektioner Natriumhydroxid (til justering af pH- værdien) Saltsyre (til justering af pH- værdien)
103 Threonine Glutamic acid Phenylalanine Water for injections Sodium hydroxide (pH adjuster) Hydrochloric acid (pH adjuster)
112 Må ikke rystes.
Do not shake.
Silapo 20000 IU/ 0, 5 ml injektionsvæske, opløsning i en fyldt injektionssprøjte
Silapo 20000 IU/0.5ml solution for injection in pre-filled syringe
4. 4). − Behandling af anæmi og reduktion af transfusionsbehov hos voksne patienter i kemoterapi for massive tumorer, malignt lymfom eller multipelt myelom og med risiko ved transfusion vurderet ud fra patientens almentilstand (fx kardiovaskulær tilstand, præeksisterende anæmi ved kemoterapistart). − Silapo kan anvendes til at øge udbyttet af autologt blod fra patienterne i et prædonationsprogram.
− Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients: o Treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis (See section 4.4). o Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis (See section 4.4). − − Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy). − Silapo can be used to increase the yield of autologous blood from patients in a predonation programme.
114 − Behandling af symptomatisk anæmi hos voksne og pædiatriske patienter med kronisk nyreinsufficiens
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patientsIn patients with chronic renal failure the medicinal product has to be administered intravenously (see section 4.4)
Der tilstræbes en hæmoglobinkoncentration på mellem 10 og 12 g/ dl (6, 2- 7, 5 mmol/ l) undtaget hos pædiatriske patienter, hvis hæmoglobinkoncentration bør ligge mellem 9, 5 og 11 g/ dl (5, 9 - 6, 8 mmol/ l).
106 The haemoglobin concentration aimed for is between 10 and 12 g/dl (6.2-7.5 mmol/l), except in paediatric patients in whom the haemoglobin concentration should be between 9.5 and 11 g/dl (5.9-6.8 mmol/l).
Det er nødvendigt, at en læge bedømmer den individuelle patients kliniske forløb og tilstand.
A nemia symptoms and sequaelea may vary with age, gender and overall burden of disesase; a physician´s evaluation of the individual patient´s clinical course and condition is necessary.
115 Dosis (IU/ kg 3 gange ugentligt)
Dose (IU/kg given 3x week)
De tilgængelige kliniske data tyder på, at patienter med meget lavt initialt hæmoglobin (< 6, 8 g/ dl eller < 4, 25 mmol/ l) kan kræve højere vedligeholdelsesdoser end patienter med initialt hæmoglobin på > 6, 8 g/ dl eller > 4, 25 mmol/ l).
107 The clinical data available suggest that those patients whose initial haemoglobin is very low (< 6.8 g/dl or < 4.25 mmol/l) may require higher maintenance doses than those whose initial haemoglobin is higher > 6.8 g/dl or > 4.25 mmol/l).
116 med en initialdosis på 450 IU/ kg subkutant 1 gang ugentligt.
Alternatively, Silapo can be administered at an initial dose of 450 IU/kg subcutaneously once weekly.
Retikulocyttalsstigning ≥ 40. 000/ mikroliter eller stigning i Hb med ≥ 1 g/ dl
108 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
118 Alle patienter, som behandles med Silapo, bør have et tilstrækkeligt jerntilskud (fx 200 mg usammensat jern oralt dagligt) under hele behandlingen.
200 mg oral elemental iron daily) throughout the course of treatment.
a) Intravenøs injektion Dosis skal administreres over mindst 1- 5 minutter, afhængigt af den totale dosis.
109 Intravenous injection The dose should be administered over at least 1-5 minutes, depending on the total dose.
119 falder ferritinværdierne i serum samtidig med stigningen i hæmatokrit.
In most cases, the ferritin values in the serum fall simultaneously with the rise in packed cell volume.
Alle disse additive faktorer ved anæmi skal også overvejes omhyggeligt, når der træffes beslutning om at øge cancerpatienters erytropoietindosis.
110 All of these additive factors of anaemia should also be carefully considered when deciding to increase the dose of erythropoietin in cancer patients.
120 anbefales der regelmæssig monitorering af reticulocyttal Hyperkalæmi er observeret i isolerede tilfælde.
Hyperkalaemia has been observed in isolated cases.
Serumelektrolytter skal monitoreres hos patienter med kronisk nyresvigt.
111 electrolytes should be monitored in chronic renal failure patients.
I lyset af ovenstående er blodtransfusion i nogle kliniske situationer være den foretrukne behandling af anæmi hos patienter med cancer.
112 In view of the above, in some clinical situations blood transfusion should be the preferred treatment for the management of anaemia in patients with cancer.
122 cerebrovaskulær hændelse (cerebral blødning og cerebral infarkt), forbigående iskæmiske anfald, dyb venetrombose, arterietrombose, pulmonal emboli, aneurismer, retinal trombose samt tilstopning af en kunstig nyre hos patienter, der får erythropoietiske midler.
Thrombotic/vascular events, such as myocardial ischaemia, myocardial infarction, cerebrovascular accidents (cerebral haemorrhage and cerebral infarction), transient ischaemic attacks, deep vein thrombosis, arterial thrombosis, pulmonary emboli, aneurysms, retinal thrombosis, and clotting of an artificial kidney have been reported in patients receiving erythropoietic agents.
Antistofforårsaget erytroblastopeni (PRCA) er blevet rapporteret efter måneder til års behandling med epoetin alfa.
113 Antibody-mediated erythroblastopenia (PRCA) has been reported after months to years of treatment with epoetin alfa.
Erytropoietins biologiske effektivitet er påvist hos forskellige forsøgsdyr in vivo (normale og anæmiske rotter, polycytæmiske mus).
114 The biological efficacy of erythropoietin has been demonstrated in various animal models in vivo (normal and anaemic rats, polycythaemic mice).
5. 2 Farmakokinetiske egenskaber
115 5.2 Pharmacokinetic properties
Dinatriumfosfat- dihydrat Natriumdihydrogenfosfat- dihydrat
Disodium phosphate dihydrate Sodium dihydrogen phosphate dihydrate Sodium chloride Calcium chloride dihydrate Polysorbate 20 Glycine Leucine Isoleucine Threonine Glutamic acid Phenylalanine Water for injections
125 Natriumklorid Kalciumklorid- dihydrat Polysorbat 20 Glycin Leucin Isoleucin Treonin Glutaminsyre Fenylalanin Vand til injektioner Natriumhydroxid (til justering af pH- værdien) Saltsyre (til justering af pH- værdien)
116 Sodium hydroxide (pH adjuster) Hydrochloric acid (pH adjuster)
126 Dette medicinske produkt er kun til engangsbrug.
This medicinal product is for single use only.
Silapo 30000 IU/ 0, 75 ml injektionsvæske, opløsning i en fyldt injektionssprøjte
Silapo 30000 IU/0.75ml solution for injection in pre-filled syringe
128 − Behandling af symptomatisk anæmi hos voksne og pædiatriske patienter med kronisk nyreinsufficiens
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patientsIn patients with chronic renal failure the medicinal product has to be administered intravenously (see section 4.4)
Der tilstræbes en hæmoglobinkoncentration på mellem 10 og 12 g/ dl (6, 2- 7, 5 mmol/ l) undtaget hos pædiatriske patienter, hvis hæmoglobinkoncentration bør ligge mellem 9, 5 og 11 g/ dl (5, 9 - 6, 8 mmol/ l).
119 The haemoglobin concentration aimed for is between 10 and 12 g/dl (6.2-7.5 mmol/l), except in paediatric patients in whom the haemoglobin concentration should be between 9.5 and 11 g/dl (5.9-6.8 mmol/l).
129 Dosis (IU/ kg 3 gange ugentligt)
Dose (IU/kg given 3x week)
De tilgængelige kliniske data tyder på, at patienter med meget lavt initialt hæmoglobin (< 6, 8 g/ dl eller < 4, 25 mmol/ l) kan kræve højere vedligeholdelsesdoser end patienter med initialt hæmoglobin på > 6, 8 g/ dl eller > 4, 25 mmol/ l).
120 The clinical data available suggest that those patients whose initial haemoglobin is very low (< 6.8 g/dl or < 4.25 mmol/l) may require higher maintenance doses than those whose initial haemoglobin is higher > 6.8 g/dl or > 4.25 mmol/l).
130 med en initialdosis på 450 IU/ kg subkutant 1 gang ugentligt.
Alternatively, Silapo can be administered at an initial dose of 450 IU/kg subcutaneously once weekly.
Retikulocyttalsstigning ≥ 40. 000/ mikroliter eller stigning i Hb med ≥ 1 g/ dl
121 Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
132 Alle patienter, som behandles med Silapo, bør have et tilstrækkeligt jerntilskud (fx 200 mg usammensat jern oralt dagligt) under hele behandlingen.
200 mg oral elemental iron daily) throughout the course of treatment.
133 falder ferritinværdierne i serum samtidig med stigningen i hæmatokrit.
In most cases, the ferritin values in the serum fall simultaneously with the rise in packed cell volume.
134 For at detektere en eventuel forekomst af manglende effektivitet hos patienter med kronisk nyresvigt anbefales der regelmæssig monitorering af reticulocyttal Hyperkalæmi er observeret i isolerede tilfælde.
Monitoring of reticulocyte count on a regular basis is recommended to detect possible occurrence of lack of efficacy in chronic renal failure patients.